Literature DB >> 11705350

Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases.

J R LaDuca1, A A Gaspari.   

Abstract

Since its discovery, the understanding of the roles for TNF-alpha in human biology and disease has grown. Receptors for TNF are found on virtually all cell types, and many physiologic processes seem to be altered by TNF-alpha. The understanding of how TNF-alpha is involved in the pathophysiology of diseases, such as inflammatory diseases, has allowed the development of new drugs that can interfere with excess TNF-alpha and thus has allowed novel therapies for rheumatoid arthritis and Crohn's disease. As the role of TNF-alpha in other diseases becomes better understood, such TNF-alpha-modulating drugs may find further applications. In the skin, TNF-alpha is prominent cytokine that seems to be important in allergic and irritant contact dermatitis and inflammatory skin conditions. Modulating TNF-alpha activity in the skin may provide therapeutic benefits for a variety of skin conditions (Table 4). Tumor necrosis factor-alpha levels are elevated in skin lesions of psoriasis. A few reports have already suggested that etanercept and infliximab may offer a therapeutic effect in patients with psoriasis. Clinical studies evaluating the true efficacy of these drugs in psoriasis are under way. Specifically, the authors and others are involved in a double-blind, placebo-controlled study to assess the efficacy of etanercept for psoriasis. Thalidomide has been used off-label with some success to treat a number of dermatologic diseases, including several inflammatory skin conditions. Etanercept and infliximab might perhaps prove efficacious for inflammatory skin conditions as well. Finally, it is possible that drugs targeting TNF-alpha may have yet-unrecognized serious side effects. Because TNF-alpha seems to be a central cytokine in UVR-induced apoptosis, the chronic use of TNF-alpha-altering drugs might increase the risk for skin cancers. Tumor necrosis factor-alpha also plays some role in cutaneous wound healing; the effect these drugs might have on this process is also unknown at this time. Certainly, much is already [table: see text] known about TNF-alpha and how it plays many central roles. This understanding has allowed the development of useful new drugs for intractable disease. As the understanding of TNF-alpha and other cytokine biology increases, so will the number of potential therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11705350     DOI: 10.1016/s0733-8635(05)70304-1

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  8 in total

1.  Folate receptor expression on murine and human adipose tissue macrophages.

Authors:  Michael J Hansen; N Achini Bandara; Philip S Low
Journal:  Inflamm Res       Date:  2015-07-07       Impact factor: 4.575

2.  [Four-year observation of etanercept therapy for rheumatoid arthritis in a single German center].

Authors:  H Schotte; M A Schorat; P Willeke; W Domschke; M Gaubitz
Journal:  Z Rheumatol       Date:  2005-05       Impact factor: 1.372

3.  A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa.

Authors:  Robert A Lee; Erica Dommasch; James Treat; Joslyn Sciacca-Kirby; Samuel Chachkin; Jennifer Williams; Daniel B Shin; James J Leyden; Carmela Vittorio; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2009-01-31       Impact factor: 11.527

4.  Cutaneous scarring: a clinical review.

Authors:  Richard Baker; Fulvio Urso-Baiarda; Claire Linge; Adriaan Grobbelaar
Journal:  Dermatol Res Pract       Date:  2010-02-10

5.  A pilot study of etanercept in the treatment of primary sclerosing cholangitis.

Authors:  Mark P Epstein; Marshall M Kaplan
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

6.  A case series of refractory cutaneous sarcoidosis successfully treated with infliximab.

Authors:  Papapit Tuchinda; Matthew Bremmer; Anthony A Gaspari
Journal:  Dermatol Ther (Heidelb)       Date:  2012-07-26

Review 7.  Biologics in dermatology: an integrated review.

Authors:  Virendra N Sehgal; Deepika Pandhi; Ananta Khurana
Journal:  Indian J Dermatol       Date:  2014-09       Impact factor: 1.494

8.  TNF-α increases the expression and activity of vitamin D receptor in keratinocytes: role of c-Jun N-terminal kinase.

Authors:  Ester Ziv; Ruth Koren; Muayad A Zahalka; Amiram Ravid
Journal:  Dermatoendocrinol       Date:  2016-01-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.